Abbott Laboratories (NYSE:ABT) Releases Earnings Results, Beats Expectations By $0.03 EPS

Abbott Laboratories (NYSE:ABT) released its earnings results on Thursday. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03, FiscalAI reports. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period last year, the company earned $1.26 earnings per share. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories updated its Q3 2026 guidance to 1.380-1.46 EPS and its FY 2026 guidance to 5.450-5.60 EPS.

Here are the key takeaways from Abbott Laboratories’ conference call:

• Abbott beat Q2 expectations with comparable sales growth of 4.8% and adjusted EPS of $1.31, while reaffirming full-year sales guidance and raising its EPS outlook to $5.45-$5.60.
• The company highlighted a strong pipeline and near-term launch cadence, including TECTONIC, Amulet 360, Libre Duo, and TactiFlex Duo, with multiple additional trials set to start in Q4.
• Nutrition trends improved meaningfully, with sales up sequentially and U.S. Ensure consumption rebounding double digits; management said WIC wins, pricing actions, and new products support a 2%-4% growth range.
• Medical devices remain a key growth driver, led by 8.5% overall device growth, accelerating electrophysiology launches, strong international traction, and continued CGM momentum above $2 billion in quarterly sales.
• Management said some areas still need work, especially U.S. structural heart and the timing of reimbursement expansions for diabetes care, but it expects second-half acceleration and improving trends into 2027.

Abbott Laboratories Trading Up 10.7%

Abbott Laboratories stock opened at $98.81 on Friday. The firm has a market cap of $172.11 billion, a PE ratio of 27.68, a P/E/G ratio of 1.54 and a beta of 0.61. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The stock’s 50 day simple moving average is $89.56 and its two-hundred day simple moving average is $102.18. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.6%. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau purchased 2,200 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On Abbott Laboratories

A number of hedge funds have recently modified their holdings of the business. Brighton Jones LLC grew its position in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Pinnacle Financial Partners Inc. lifted its position in Abbott Laboratories by 21.0% during the third quarter. Pinnacle Financial Partners Inc. now owns 122,698 shares of the healthcare product maker’s stock worth $16,434,000 after buying an additional 21,301 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after buying an additional 162 shares during the last quarter. United Bank grew its holdings in Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after buying an additional 2,001 shares in the last quarter. Finally, FSA Wealth Management LLC increased its stake in shares of Abbott Laboratories by 12.9% in the 3rd quarter. FSA Wealth Management LLC now owns 885 shares of the healthcare product maker’s stock worth $119,000 after acquiring an additional 101 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ABT shares. Benchmark cut their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Sanford C. Bernstein reduced their price target on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Barclays cut their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. Bank of America lowered their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Finally, Robert W. Baird assumed coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $117.61.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported Q2 adjusted EPS of $1.31, topping estimates, while revenue rose 13% year over year and sales growth was broad-based across medical devices, diagnostics, and nutrition. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: The company raised 2026 adjusted EPS guidance to $5.45-$5.60 from $5.38-$5.58, which suggests management is seeing better profitability trends than Wall Street expected. Abbott raises 2026 profit forecast on heart device strength
• Positive Sentiment: Investor sentiment improved because demand for Abbott’s heart devices and diagnostics appears to be strengthening, especially after management pointed to a better second-half outlook and continued momentum in those segments. Why Abbott Stock Jumped Today
• Neutral Sentiment: Abbott continues to trade well above its recent 50-day average, but it remains below its 200-day average, so the longer-term trend is still mixed despite the earnings-driven rebound.
• Negative Sentiment: Some headlines note that the stock had been under pressure earlier this year, and while the latest results helped, concerns about the broader trend and valuation are not fully gone. Is Abbott Laboratories (ABT) Below Fair Value After Its 31% Fall?

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.